OMNi-BiOTiC® PRO-VI5 

Synbiotyk do walki z infekcjami wirusowymi:

• W trakcie infekcji wirusowych górnych dróg oddechowych
• W trakcie biegunek wywołanych rotawirusami
• Wirusowe infekcje zapalene przewodu pokarmowego
• Wspomagająco przy ciężkich bakteryjnych zapaleniach płuc

Opakowanie zawiera 14 saszetek.

Działanie:

OMNi-BiOTiC® PRO Vi 5 – proszek to suplement diety pełniący funkcję probiotyku. Prace badawcze nad wpływem bakterii na infekcja wirusowe rozpoczął się dużo wcześniej niż temat stał się modny. Od 2014 roku zaczęto katalogować badania i wnioski o kluczowym wpływie mikrobiomu na odporność przeciwwirusową. OMNi-BiOTiC® PRO Vi 5 to połączenie kilku bardzo skutecznych szczepów bakterii w walce z wirusami górnych i dolnych dróg oddechowych, w tym najczęściej wywołującego hospitalizację u dzieci Syncytialnego wirusa oddechowego. Skuteczność także potwierdzona została przy rotawirusach wywołujących biegunki oraz objawy gastryczne przewodu pokarmowego u dzieci i dorosłych. Synergia zastosowanych szczepów stymuluje, wspiera bądź aktywuje aż 10 z 13 poznanych mechanizmów obronnych w walce z wirusami.

Skład:

5  szczepów:

1. Lactobacillus delbrueckii ssp. bulgaricus LB2 (LMG P-21905)
2. Lactobacillus rhamnosus SP1 (DSM 21690)
3. Lactobacillus reuteri DSM 12246
4. Lactobacillus rhamnosus CRL1505(DSM 29673)
5. Bifidobacterium animalis ssp. lactis DSM 15954

Zalecane spożycie:

Profilaktycznie, 1 x 1 saszetka : na czczo

• W trakcie sezonu grypowego profilaktycznie
• Przy zmianach na płucach po przebytych infekcjach dróg oddechowych

Wskazania infekcyjne, 2 x 1 saszetka rano na czczo i przed kolacją:

• W trakcie infekcji wirusowych górnych dróg oddechowych
• W trakcie biegunek wywołanych rotawirusami
• Wirusowe zapalenie przewodu pokarmowego
• Wspomagająco przy ciężkich bakteryjnych zapaleniach płuc

Zalecaną porcję rozpuścić w około 100 ml zimnej / letniej wody.  Pozostaw na min. 1 minut (czas potrzebny na obudzenie i aktywację bakterii).  Następnie delikatnie zamieszaj przed spożyciem. Spożywać na czczo, najlepiej przed śniadaniem lub przed kolacją.

JAK PRZECHOWYWAĆ OMNi-BiOTiC®?

Synbiotyki OMNi-BiOTiC® powinny być przechowywane poza zasięgiem dzieci w pomieszczeniach o temperaturze od 5-30°C. Nie ma konieczności przechowywania w lodówce.

Badania:

Badania:

Badania na bazie, których powstała receptura i skład oraz wskazania stosowania OMNi-BiOTiC® PRO-Vi :

[1] Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–7.

[2] Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, et al. Influenza. Vol. 4, Nature Reviews Disease Primers. 2018. p. 1–21.

[3] Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Vol. 285, Virus Research. Elsevier B.V.; 1. p. 198018.

[4] Groves HT, Higham SL, Moffatt MF, Cox MJ, Tregoning JS, Bomberger JM. Respiratory Viral Infection Alters the Gut Microbiota by Inducing Inappetence Downloaded from. 2020;

[5] Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection.

[6] Dumas A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles 1. The role of the lung microbiota and the gut–lung axis in respiratory infectious diseases. Vol. 20, Cellular Microbiology. 2018.

[7] Budden KF, Gellatly SL, A Wood DL, Cooper MA, Morrison M, Hugenholtz P, et al. Emerging pathogenic links between the microbiota and the gut–lung axis. 2016.

[8] Dickson RP. The microbiome and critical illness. Vol. 4, The Lancet Respiratory Medicine. Lancet Publishing Group; 1. p. 59–72.

[9] Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. Management of COVID-19: the Zhejiang experience. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May;49(2):147–57.

[10] Al Kassaa I, Hober D, Hamze M, Chihib NE, Drider D. Antiviral Potential of Lactic Acid Bacteria and Their Bacteriocins. Vol. 6, Probiotics and Antimicrobial Proteins. Springer New York LLC; 2014. p. 177–85.

[11] Maeda N, Nakamura R, Hirose Y, Murosaki S, Yamamoto Y, Kase T, et al. Oral administration of heat-killed Lactobacillus plantarum L-137 enhances protection against influenza virus infection by stimulation of type I interferon production in mice. Int Immunopharmacol [Internet]. 2009 Aug [cited 2020 Mar 24];9(9):1122–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19410659

[12] Boge T, Rémigy M, Vaudaine S, Tanguy J, Bourdet-Sicard R, van der Werf S. A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomized controlled trials. Vaccine [Internet]. 2009 Sep 18 [cited 2020 Mar 24];27(41):5677–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19615959

[13] Mercenier A, Pavan S, Pot B. Probiotics as Biotherapeutic Agents: Present Knowledge and Future Prospects. Curr Pharm Des. 2005 Mar;9(2):175–91.

[14] Villena J, Oliveira MLS, Ferreira PCD, Salva S, Alvarez S. Lactic acid bacteria in the prevention of pneumococcal respiratory infection: Future opportunities and challenges. Vol. 11, International Immunopharmacology. Int Immunopharmacol; 1. p. 1633–45.

[15] Wang Z, Chai W, Burwinkel M, Twardziok S, Wrede P, Palissa C, et al. Inhibitory Influence of Enterococcus faecium on the Propagation of Swine Influenza A Virus In Vitro. PLoS One [Internet]. 2013 Jan 7 [cited 2020 Mar 24];8(1):e53043. Available from: http://www.ncbi.nlm. nih.gov/pubmed/23308134

[16] Serkedjieva J, Danova S, Ivanova I. Antiinfluenza virus activity of a bacteriocin produced by Lactobacillus delbrueckii. Appl Biochem Biotechnol – Part A Enzym Eng Biotechnol. 2000;88(1–3):285–98.

[17] Conti C, Malacrino C, Mastromarino P. Inhibition of herpes simplex virus type 2 by vaginal lactobacilli. J Physiol Pharmacol [Internet]. 2009 Dec 1 [cited 2020 Dec 10];60(SUPPL. 6):19–26. Available from: https://europepmc.org/article/med/20224147

[18] Tuyama ACG, Cheshenko N, Carlucci MJ, Li J-H, Goldberg CL, Waller DP, et al. ACIDFORM Inactivates Herpes Simplex Virus and Prevents Genital Herpes in a Mouse Model: Optimal Candidate for Microbicide Combinations. Vol. 795, ACIDFORM Prevents Genital Herpes • JID. 2006.

[19] Martin LS, Mc Dougal JS, Loskoski SL. Disinfection and inactivation of the human t lymphotropic virus type iii/ lymphadenopathy-associated virus. J Infect Dis. 1985 Aug;152(2):400–3.

[20] Martín V, Maldonado A, Fernández L, Rodríguez JM, Connor 1. Inhibition of human immunodeficiency virus type 1 by lactic acid bacteria from human breastmilk. Breastfeed Med. 2010;5(4):153–8.

[21] Moore MD, Jaykus L-A. Virus-Bacteria Interactions: Implications and Potential for the Applied and Agricultural Sciences. 2018;

[22] Kassaa I Al, Hober D, Hamze M, Caloone D, Dewilde A, Chihib N eddine, et al. Vaginal Lactobacillus gasseri CMUL57 can inhibit herpes simplex type 2 but not Coxsackievirus B4E2. Arch Microbiol. 2015 Jun 26;197(5):657–64.

[23] Miquel S, Martín R, Rossi O, Bermúdez-Humarán LG, Chatel JM, Sokol H, et al. Faecalibacterium prausnitzii and human intestinal health. Current Opinion in Microbiology. 2013.

[24] Varyukhina S, Freitas M, Bardin S, Robillard E, Tavan E, Sapin C, et al. Glycan-modifying bacteria-derived soluble factors from Bacteroides thetaiotaomicron and Lactobacillus casei inhibit rotavirus infection in human intestinal cells. Microbes Infect. 2012 Mar 1;14(3):273–8.

[25] Jung. Beeinflussung von sekretorischen IgA-Defiziten bei Sportstudierenden durch Nahrungsergjnzungsmittel. 1999;

[26] BOTIC T, KLINGBERG T, WEINGARTL H, CENCIC A. A novel eukaryotic cell culture model to study antiviral activity of potential probiotic bacteria. Int J Food Microbiol [Internet]. 2007 Apr 30 [cited 2020 Nov 19];115(2):227–34. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0168160506005824

[27] Larsen N, Michaelsen KF, Pćrregaard A, Vogensen FK, Jakobsen M. A comparative study on adhesion and recovery of potential probiotic strains of Lactobacillus spp. by in vitro assay and analysis of human colon biopsies. Microb Ecol Health Dis [Internet]. 2009 Jan 11 [cited 2020 Nov 19];21(2):95–9. Available from: https://www.tandfonline.com/doi/full/10.1080/08910600902907632

[28] Shornikova AV, Casas IA, Mykkänen H, Salo E, Vesikari 1. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J [Internet]. 1997 Dec [cited 2020 Nov 19];16(12):1103–7. Available from: https://pubmed.ncbi.nlm.nih.gov/9427453/

[29] Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: A systematic review of published randomized, double-blind, placebo-controlled trials. In: Journal of Pediatric Gastroenterology and Nutrition [Internet]. Centre for Reviews and Dissemination (UK); 2001 [cited 2020 Nov 19]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK68774/

[30] Kawase M, He F, Kubota A, Harata G, Hiramatsu M. Oral administration of lactobacilli from human intestinal tract protects mice against influenza virus infection. Lett Appl Microbiol [Internet]. 2010 Apr 5 [cited 2020 Nov 19];51(1):no-no. Available from: http://doi.wiley.com/10.1111/j.1472-765X.2010.02849.x

[31] Maragkoudakis PA, Chingwaru W, Gradisnik L, Tsakalidou E, Cencic A. Lactic acid bacteria efficiently protect human and animal intestinal epithelial and immune cells from enteric virus infection. Int J Food Microbiol [Internet]. 2010 Jul [cited 2020 Dec 10];141(SUPPL.). Available from: https://pubmed.ncbi.nlm.nih.gov/20106541/

[32] Pant N, Marcotte H, Brüssow H, Svensson L, Hammarström 1. Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies. BMC Microbiol [Internet]. 2007 [cited 2020 Nov 19];7. Available from: https://pubmed.ncbi.nlm.nih.gov/17900343/

[33] Miettinen M, Pietilä TE, Kekkonen RA, Kankainen M, Latvala S, Pirhonen J, et al. Nonpathogenic Lactobacillus rhamnosus activates the inflammasome and antiviral responses in human macrophages. Gut Microbes [Internet]. 2012 Nov [cited 2020 Nov 19];3(6):510–22. Available from: https://pubmed.ncbi.nlm.nih.gov/22895087/

[34] Tomosada Y, Chiba E, Zelaya H, Takahashi T, Tsukida K, Kitazawa H, et al. Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection. BMC Immunol [Internet]. 2013 Aug 15 [cited 2020 Nov 19];14(1). Available from: https://pubmed.ncbi.nlm.nih.gov/23947615/

[35] Villena J, Chiba E, Tomosada Y, Salva S, Marranzino G, Kitazawa H, et al. Orally administered Lactobacillus rhamnosus modulates the respiratory immune response triggered by the viral pathogen-associated molecular pattern poly(I:C). BMC Immunol [Internet]. 2012 [cited 2020 Nov 19];13:53. Available from: /pmc/articles/PMC3460727/?report=abstract

[36] Zelaya H, Tsukida K, Chiba E, Marranzino G, Alvarez S, Kitazawa H, et al. Immunobiotic lactobacilli reduce viral- associated pulmonary damage through the modulation of inflammation-coagulation interactions. Int Immunopharmacol [Internet]. 2014 Mar [cited 2020 Nov 19];19(1):161–73. Available from: https://pubmed.ncbi.nlm.nih.gov/24394565/

[37] Kitazawa H, Villena J. Modulation of respiratory TLR3-anti-viral response by probiotic microorganisms: Lessons learned from Lactobacillus rhamnosus CRL1505 [Internet]. Vol. 5, Frontiers in Immunology. Frontiers Research Foundation; 2014 [cited 2020 Nov 19]. Available from: https://pubmed.ncbi.nlm.nih.gov/24860569/

[38] Salva S, Villena J, Alvarez S. Immunomodulatory activity of Lactobacillus rhamnosus strains isolated from goat milk: Impact on intestinal and respiratory infections. Int J Food Microbiol [Internet]. 2010 Jun 30 [cited 2020 Nov 19];141(1–2):82–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0168160510001534

[39] Taipale T, Pienihkkinen K, Isolauri E, Larsen C, Brockmann E, Alanen P, et al. Bifidobacterium animalis subsp. lactis BB- 12 in reducing the risk of infections in infancy. Br J Nutr [Internet]. 2011 Feb 14 [cited 2020 Dec 10];105(3):409– Available from: https://pubmed.ncbi.nlm.nih.gov/20863419/

[40] Khavkin AI, Keshishyan ES. Effectiveness of the probiotic Bifidobacterium (Bifidobacterium animalis subsp. lactis) strain DSM N 15954 in functional digestive disorders in infants: results of a prospective, open, observational study. Vopr Det Dietol. 2014;12(2):30–6.

[41] Smith TJ, Rigassio-Radler D, Denmark R, Haley T, Touger-Decker R. Effect of Lactobacillus rhamnosus LGG® and Bifidobacterium animalis ssp. lactis BB-12® on health-related quality of life in college students affected by upper respiratory infections. Br J Nutr [Internet]. 2013 Jun [cited 2020 Nov 19];109(11):1999–2007. Available from: https://pubmed.ncbi.nlm.nih.gov/23020819/

[42] Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – A randomised, double-blind, placebo-controlled study. Br J Nutr [Internet]. 2009 [cited 2020 Nov 19];101(11):1722–6. Available from: https://pubmed.ncbi.nlm.nih.gov/18986600/